Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Merck & Company Inc (MRK)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Merck&Co's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
92.67 +0.35    +0.38%
15:41:58 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
ISIN:  US58933Y1055 
CUSIP:  58933Y105
  • Volume: 6,756,828
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 91.76 - 92.75
Merck&Co 92.67 +0.35 +0.38%
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2022
31/03
2021
31/12
2021
30/09
2021
30/06
Total Current Assets 31184 30266 31058 28665
Cash and Short Term Investments 8928 8096 10016 8575
Cash - - - -
Cash & Equivalents 8556 8096 10016 8575
Short Term Investments 372 - - -
Total Receivables, Net 9828 9230 8571 7843
Accounts Receivables - Trade, Net 9828 9230 8571 7843
Total Inventory 5774 5953 5603 5499
Prepaid Expenses - - - -
Other Current Assets, Total 6654 6987 6868 6748
Total Assets 106668 105694 93494 90688
Property/Plant/Equipment, Total - Net 19747 19279 18565 18064
Property/Plant/Equipment, Total - Gross 38245 37471 36720 36300
Accumulated Depreciation, Total -18498 -18192 -18155 -18236
Goodwill, Net 21258 21264 18862 18873
Intangibles, Net 23022 22933 13384 13622
Long Term Investments 959 966 1013 1105
Note Receivable - Long Term - - - -
Other Long Term Assets, Total 10498 10986 10612 10359
Other Assets, Total - - - -
Total Current Liabilities 22316 23872 23728 21906
Accounts Payable 3715 4609 3366 3897
Payable/Accrued - - - -
Accrued Expenses 14051 13859 14214 12888
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 1208 2412 3534 2488
Other Current liabilities, Total 3342 2992 2614 2633
Total Liabilities 65785 67510 57700 57394
Total Long Term Debt 30586 30690 22907 24033
Long Term Debt 30586 30690 22907 24033
Capital Lease Obligations - - - -
Deferred Income Tax 3071 3441 1527 1489
Minority Interest 70 73 69 94
Other Liabilities, Total 9742 9434 9469 9872
Total Equity 40883 38184 35794 33294
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 1788 1788 1788 1788
Additional Paid-In Capital 44275 44238 44149 44039
Retained Earnings (Accumulated Deficit) 56252 53696 51691 48777
Treasury Stock - Common -57063 -57109 -57244 -56682
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total -4369 -4429 -4590 -4628
Total Liabilities & Shareholders' Equity 106668 105694 93494 90688
Total Common Shares Outstanding 2528.38 2527.6 2525.32 2532.75
Total Preferred Shares Outstanding - - - -
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MRK Comments

Write your thoughts about Merck & Company Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Christopher Zingone
Christopher Zingone May 20, 2022 12:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This will be 120+ soon
black cat
black cat May 16, 2022 12:28PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ma e' sui massimi da sempre? che t.p. si puo' immaginare a questo punto ?
Rob Roo
Rob Roo Apr 28, 2022 1:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🚀🚀🚀🚀🚀🚀🚀🌜
Taras Khomitsky
Taras Khomitsky Apr 28, 2022 8:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good, even great reasults in first quater of 2022.Let's hope to go back to 86-87 territory
Fever Factory
Fever Factory Apr 20, 2022 5:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention.
Fever Factory
Fever Factory Apr 20, 2022 5:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.
Fever Factory
Fever Factory Apr 20, 2022 5:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.
William Hineser
William Hineser Apr 02, 2022 9:07AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It was 22 in 1995. Do the math and look at the products.
Ahmad Amzar Sohaimi
Ahmad Amzar Sohaimi Mar 24, 2022 9:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hope can break 80 this week
Amr Taher
Amr Taher Mar 22, 2022 1:16PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It should reach 120 soon
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email